Chronic insulin exposure is known to be associated with insulin resistance. Ace Therapeutics utilizes chronic insulin exposure to induce in vitro insulin resistance models. Our efficient service process and reliable in vitro insulin resistance models are designed to help our clients achieve breakthroughs in researching diabetes mechanisms, screening drugs, and developing innovative therapies.
Fig. 1 Chronic insulin treatment impairs insulin signalling in both 3T3-L1 and SGBS, causing insulin resistance. (Rossi, A.; et al., 2020)
Ace Therapeutics is dedicated to leveraging our expertise to develop highly controllable and reproducible in vitro models of insulin resistance for organizations engaged in diabetes research and therapy development worldwide. Please contact us for more details and we will be happy to assist you.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.